Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Sections
Cancer Drug Development
share announcement

Cancer Drug Development

A section of Cancers (ISSN 2072-6694).

Section Information

Cancer represents a major public health challenge and is the second leading cause of death in the United States. The World Health Organization estimates that, by the year 2035, there will be 24 million new cancer cases and 14.4 million cancer-related deaths each year. Thanks to the remarkable progress in our understanding of cancer initiation, promotion, and progression, as well as technological advances and refinements of computational tools, we have numerous therapeutic options to detect, prevent, and treat cancer. Nevertheless, refractory malignancy, cancer drug resistance, unacceptable adverse effects, and high costs for anticancer drugs are some of the challenges for patients with oncological diseases. Hence, the discovery and development of effective, safe, and affordable drugs to diagnose, prevent, and manage malignant diseases are urgently needed. As articulated in the “Cancer Moonshot” initiative, we need to accelerate scientific discovery in oncology, foster greater collaboration among cancer researchers and other stake holders, and improve the sharing of cancer-related data. With the enhancement of our knowledge on the complexity of cancer phenotypes and genotypes as well as the discovery of emerging cancer hallmarks, we are in an exciting era of cancer therapeutics. The purpose of this section is to rapidly publish quality manuscripts on all aspects of cancer drug development based on preclinical and clinical research. We hope to receive submissions based on novel findings on cancer preventive and therapeutic effects of natural and synthetic compounds, with an understanding of the related cellular and molecular mechanisms of action. Studies on botanical drugs, extracts, fractions, or mixtures are only considered when the identification of active constituents are reported. Original research papers reporting in vitro and in vivo data, clinical trials, authoritative systematic, narrative and perspective reviews, commentaries, and reports on meta-analysis will be considered. Various relevant topics include but are not limited to the following:

  • Anticancer drug discovery;
  • Drug development;
  • Chemotherapeutic agents;
  • Hormonal agents;
  • Targeted agents;
  • Immunological agents;
  • Preventive therapeutic agents;
  • Radiopharmaceuticals;
  • Combination therapies;
  • Structure-activity relationship;
  • Dereplication and molecular networking;
  • Pharmacokinetics of anticancer agents;
  • Drug resistance;
  • Emerging hallmarks;
  • Precision medicine;
  • Personalized therapy;
  • Novel drug formulation;
  • Novel drug delivery;
  • Artificial intelligence.

Editorial Board

Topical Advisory Panel

Special Issues

Following special issues within this section are currently open for submissions:

Topical Collections

Following topical collections within this section are currently open for submissions:

Papers Published

Back to TopTop